Quick Takeaways
- ASTRAZENECA PLC filed SCHEDULE 13G/A for Conduit Pharmaceuticals Inc. Common Stock, par value $0.0001 per share (CDT).
- Disclosed ownership: 1.1%.
- Date of event: 31 Mar 2025.
ASTRAZENECA PLC - 31 Mar 2025 SCHEDULE 13G/A Report for Conduit Pharmaceuticals Inc. Common Stock, par value $0.0001 per share (CDT)
- Filing Manager
- ASTRAZENECA PLC
- Reporting Manager
- AstraZeneca PLC
- Symbol
- CDT
- Shares outstanding
- 6,717,455 shares
- Disclosed Ownership
- 73,892 shares
- Ownership
- 1.1%
- Form type
- SCHEDULE 13G/A
- Filing time
- 10 Apr 2025, 06:00:23 UTC
- Date of event
- 31 Mar 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"ASTRAZENECA PLC disclosed 1.1% ownership in Conduit Pharmaceuticals Inc. Common Stock, par value $0.0001 per share (CDT) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 10 Apr 2025, 06:00.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| AstraZeneca PLC | 1.1% | 73,892 | 73,892 | 0 | /s/ Adrian Kemp | Adrian Kemp, Company Secretary | |
| AstraZeneca AB | 1.1% | 73,892 | 73,892 | 0 | /s/ Lars-Johan Cederbrant | Lars-Johan Cederbrant, Director and CFO |